May 30, 2018 05:43 PM EDT
R&D
Pharma

Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

Brittany Meiling

San Fran’s I/O dar­ling Nek­tar Ther­a­peu­tics $NK­TR is hand­ing off ac­cess to its pop­u­lar can­cer can­di­date NK­TR-214 to see how the ther­a­py fairs when paired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times